【摘要】 目的 觀察依托咪酯乳劑復合舒芬太尼用于全麻下喉罩置入的血流動力學變化。 方法 選擇2009年4月-2010年2月間，46例需全麻手術、適合使用喉罩，美國麻醉醫師協會（ASA）Ⅰ～Ⅱ級，年齡18～60歲的患者，隨機分為兩組:依托咪酯乳劑組（E組）23 例，靜脈推注咪達唑侖0.05 mg/kg，依托咪酯乳劑0.3 mg/kg；依托咪酯乳劑+舒芬太尼組（ES組）23 例，靜脈推注咪達唑侖0.05 mg/kg，依托咪酯乳劑0.15 mg/kg，加舒芬太尼0.5 mg/kg，誘導后置入喉罩，記錄患者誘導前、用藥后1 min、喉罩置入后1 min的心率（HR）、平均動脈壓（MAP）以及評估喉罩置入條件的6項指標（張口困難分級、置入喉罩困難分級、舌咽反射、干咳干嘔反射、肢動反應及喉痙攣分級），同時記錄呼吸暫停時間。 結果 ES組能提供更好的喉罩置入條件，且能減少舌咽反射和肢體反應， 更能保證喉罩置入時血流動力學的穩定。 結論 依托咪酯乳劑復合舒芬太尼能為全麻喉罩置入時提供更好的條件，且能保證更好的血流動力學穩定。【Abstract】 Objective To investigate the hemodynamics changes when etomidate combined with sufentanil was applied for laryngeal mask airway insertion under the general anaesthesia. Methods From April 2009 to February 2010, 46 patients requiring general anesthesia using laryngeal mask airway (LMA) (American Society of Anesthesiologists (ASA)Ⅰ-Ⅱ) aged 18-60 were randomly divided into two groups: 23 in etomidate emulsion group (group E) underwent the intravenous injection with midazolm (0.3 mg/kg) and etomidate (0.05 mg/kg); 23 in etomidate emulsion + sufentanil group (group ES) underwent the intravenous injection with etomidate (0.15 mg/kg), midazolm (0.05 mg/kg), and sufentanil 0.5 mg/kg. The patients were evaluated by six indexes of LMA insertion (mouth opening, swallowing reflex, cough reflex,vomiting reflex, body motion, and laryngospasm classification). After the anesthesia induction, LMA was inserted. The blood pressure (BP), heart rate (HR), and mean arterial pressure (MAP) were recorded before anesthesia induction one minute after the injection and one minute after LMA insertion. Meanwhile, the apnea time was recorded. Results Compared with group E, group ES offered better anesthesia for LMA insertion, less swallowing reflex and body motion, and more stable haemodynamics. Conclusion Etomidate combined with sufentanil provides good condition for LMA insertion under the general anaesthesia with steady haemodynamics.
摘要: 目的 探討自體骨髓間充質干細胞(MSCs)小腸黏膜下層(SIS)支架復合物移植于陳舊性心肌梗死區域后細胞的存活、支架的降解情況及其對心功能的影響。 方法 將16只黑山羊按隨機數字表法分為兩組，每組8只。實驗組：建立心肌梗死模型，抽取自體骨髓,經體外分離MSCs,進行培養、傳代、BrdU標記、與SIS支架復合，并于心肌梗死6周時將MSCs-SIS復合物補片移植至陳舊性心肌梗死區；對照組：建立心肌梗死模型。于移植后6周行超聲心動圖、HE染色及免疫組織化學檢測。 結果 MSCs-SIS植入心肌梗死區2周時在補片區可見大量炎性細胞浸潤；6周時淋巴細胞浸潤消失，SIS部分降解，移植區見大量移植細胞存活。MSCs-SIS植入體內后6周時，實驗組每搏輸出量(42.81±4.91 ml vs. 37.06±4.75 ml)、射血分數(59.20%±5.41% vs. 44.56%±4.23%)、室壁增厚率（54.51%±8.60% vs. 43.36%±8.91%）、舒張期E峰 (54.85±6.35 cm/s vs. 43.14±4.81 cm/s)顯著高于對照組(Plt;0.05)，左心室收縮期末容積(29.75±5.98 ml vs. 46.25±6.68 ml)、舒張期末容積(72.55±8.13 ml vs. 83.31±8.61 ml)顯著低于對照組(Plt;0.05)。 結論 SIS作為支架移植MSCs有利于移植細胞存活，對陳舊性心肌梗死后心功能有明顯的改善作用。
